← All indications
Leukemia, B-Cell
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
Subtype terms (2)
More specific conditions that are subtypes of Leukemia, B-Cell in the MeSH hierarchy.
- Leukemia, Lymphocytic, Chronic, B-Cell
623 drugs (231 approved, 392 experimental)
- Leukemia, Prolymphocytic, B-Cell
22 drugs (15 approved, 7 experimental)
Drugs by status
Phase 4 trials (1)
Phase 3 trials (5)
Phase 2 trials (55)
- mercaptopurine
- acalabrutinib
- urea
- bay94-9392
- car t cells
- lenalidomide
- clofarabine
- nelarabine
- prednisone
- doxorubicin
- naltrexone
- lapatinib
- epacadostat
- nivolumab
- itacitinib
- lenvatinib
- allogeneic stem cells
- vincristine
- panobinostat
- pegaspargase
- pneumococcal 13-valent conjugate vaccine
- ifosfamide
- carboplatin
- allogeneic hematopoietic stem cells
- cyclophosphamide
- alemtuzumab
- bortezomib
- anti-cd19/20-car vector-transduced t cells
- cd22 car-t cells
- fludarabine
- +25 more
Phase 1 trials (57)
- roflumilast
- afm11
- venetoclax
- blinatumomab
- diltiazem
- entospletinib
- obinutuzumab
- Sovleplenib
- idelalisib
- pembrolizumab
- inebilizumab
- pentostatin
- tirabrutinib
- rabeprazole
- fluconazole
- urelumab
- nemtabrutinib
- autologous cd19 car+ egftt + t cells
- cart22
- clarithromycin
- gamma-delta t cells
- incb040093
- ocaratuzumab
- pomalidomide
- voriconazole
- copanlisib
- cd19.car-ankt cells
- hiv-1 specific car-t cells
- icar19 car-t cells
- cd19/cd20 bispecific car-t cells
- +27 more
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (25)
- Spectrum Pharmaceuticals
- Advancell - Advanced In Vitro Cell Technologies, S.A.
- Immunomedics
- Novartis
- Asana BioSciences
- Bayer
- Hebei Senlang Biotechnology Inc., Ltd.
- Shanghai GeneChem Co., Ltd.
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- Hebei University
- Eastern Hepatobiliary Surgery Hospital
- Nanjing Medical University
- Shenzhen Geno-Immune Medical Institute
- Stanford University
- Vilnius University
- Chongqing Medical University
- Soochow University
- Université catholique de Louvain
- Uppsala University
- Karolinska Institute
- Swedish Cancer Society
- Nexus Oncology Ltd
- People's Liberation Army of China
- Chongqing Precision Biotech Co., Ltd
- St. Jude Children's Hospital
Organization Involved with Phase 1 Indications (32)
- Celgene
- Bristol-Myers Squibb
- Merck
- CARsgen Therapeutics, Ltd.
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Affimed GmbH
- Huazhong University of Science and Technology
- University of Pennsylvania
- Anhui Medical University
- Baylor University
- University of London
- University of Washington
- Jilin University
- Peking University
- University of Cincinnati
- Zhejiang University
- Shenzhen immune gene therapy research institute
- Jiao Tong University
- Molecular Templates
- Weifang People's Hospital
- Henan Medical University
- Methodist Cancer Center, Houston, Texas
- State University of New York, Buffalo
- Guizhou Medical University
- Immune Cell Therapy Inc.
- Gracell Biotechnology Ltd.
- China Immunotech
- Ludaopei Hospital
- Aeon Therapeutics (Shanghai) Co., Ltd.
- The First People's Hospital of Yunan Province
- +2 more
Organization Involved with Other Experimental Indications (4)